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Abstract
Background: Mitochondrial dysfunction, oxidative stress and their interplay are core pathological features of
Parkinson’s disease. In dopaminergic neurons, monoamines and their metabolites provide an additional source of
reactive free radicals during their breakdown by monoamine oxidase or auto-oxidation. Moreover, mitochondrial
dysfunction and oxidative stress have a supraadditive impact on the pathological, cytoplasmic accumulation of
dopamine and its subsequent release. Here we report the effects of a novel series of potent and selective MAO-B
inhibitory (hetero)arylalkenylpropargylamine compounds having protective properties against the supraadditive
effect of mitochondrial dysfunction and oxidative stress.
Results: The (hetero)arylalkenylpropargylamines were tested in vitro, on acute rat striatal slices, pretreated with the
complex I inhibitor rotenone and in vivo, using the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced
acute, subchronic, and chronic experimental models of Parkinson’s disease in mice. The compounds exhibited
consistent protective effects against i) in vitro oxidative stress induced pathological dopamine release and the
formation of toxic dopamine quinone in the rat striatum and rescued tyrosine hydroxylase positive neurons in the
substantia nigra after rotenone treatment; ii) in vivo MPTP-induced striatal dopamine depletion and motor
dysfunction in mice using acute and subchronic, delayed application protocols. One compound (SZV558) was also
examined and proved to be protective in a chronic mouse model of MPTP plus probenecid (MPTPp) administration, which
induces a progressive loss of nigrostriatal dopaminergic neurons.
Conclusions: Simultaneous inhibition of MAO-B and oxidative stress induced pathological dopamine release by the novel
propargylamines is protective in animal models and seems a plausible strategy to combat Parkinson’s disease.
Keywords: Propargylamine, Parkinson’s disease, Mitochondrial dysfunction, Mono-aminooxidase B, Neuroprotection,
Dopamine
Background
Parkinson’s disease (PD) is a chronic neurodegenerative dis-
order, characterized by the progressive degeneration of the
nigrostriatal dopaminergic pathway. The disease is mani-
fested in various motor symptoms such as bradykinesia,
postural instability, resting tremor and muscle rigidity,
appearing only at an advanced (70 %) stage of degeneration.
Moreover, as the pathology progresses, degeneration extends
to other cortical and subcortical non-dopaminergic path-
ways, responsible for non–motor symptoms such as depres-
sion, delusions and cognitive decline.
The current treatment of PD relies on the replacement
of dopamine (DA) by its precursor, levo-DOPA (L-DOPA)
or dopaminergic agonists [1, 2]. A necessary prerequisite
for these approaches, however, is the presence of function-
ing dopaminergic nerve terminals in the striatum, meaning
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the disease becomes increasingly refractory to pharmaco-
logical intervention through its progression. Moreover,
these approaches have many side effects e.g. dyskinesia or
motor fluctuations, which cannot easily be tolerated during
life-long treatment and could be a starting point for further
complications, such as dopamine dysregulation syndrome
or impulse control disorder [3]. An alternative approach
used in existing therapies is based on the inhibition of en-
zymes involved in the metabolic degradation of dopamine
(monoamine oxidase, MAO, catechol-O-methyltransferase,
COMT). This is primarily used as an add-on therapy [4].
Selective monoamine oxidase-B (MAO-B) inhibitors inhibit
the enzyme responsible for the intracellular degradation of
dopamine, thereby increasing dopamine availability in the
nigrostriatal pathway and prolonging the effectiveness of L-
DOPA replacement therapy. In addition, certain MAO-B
inhibitors, such as selegiline or rasagiline, are thought to be
neuroprotective against dopaminergic cell death. Rasa-
giline, which is a selective and irreversible inhibitor of
MAO-B, increases cell survival in cell culture models of
PD [5, 6]. This protective effect, however, has not been
so convincingly replicated in the clinic [7, 8]. In the re-
cent ADAGIO (Attenuation of Disease Progression
with Azilect Given Once-Daily) trial, a delayed start
study design was applied to separate symptomatic
benefit from disease-modifying effect, however, the re-
sults failed to define a clear, dose-dependent disease-
modifying action of rasagiline [7]. Despite considerable
efforts, at present, there is no single therapeutic agent
able to halt or slow down the progression of neurode-
generation in clinical settings [9, 10].
One potential reason for this failure is that the process
leading to neuronal death is remarkably complex, involv-
ing self-amplifying mechanisms on subcellular, cellular
and system levels and drugs that act at a single target
are unlikely to have significant influence on the final
outcome. [11]. Systemic mitochondrial dysfunction, a
subsequent oxidative stress, their interplay and the con-
sequent dysregulation of dopamine pools are core patho-
logical features of PD, which play a determinant role in
the development of the relatively selective degeneration
of nigrostriatal dopaminergic neurons [12–14]. Systemic
mitochondrial dysfunction can be modelled in animal
experiments by chronic low dose continuous exposure
of rats to the mitochondrial complex I inhibitor rote-
none, which reproduces the major anatomical, neuro-
chemical and behavioral hallmarks of Parkinson’s disease
in rats [15–17]. More recently, it was confirmed that the
same neurochemical alterations could be reproduced by
in vitro pretreatment of striatal slices with rotenone,
overcoming the weak reproducibility of the in vivo rote-
none model [18, 19].
Using rotenone-induced models, we have previously
shown that mitochondrial dysfunction and oxidative
stress have a supraadditive impact on the pathological,
cytoplasmic accumulation of dopamine and its subse-
quent release in striatal slices from rats [16, 20]. More-
over, in dopaminergic neurons, monoamines and their
metabolites provide an additional source of highly react-
ive free radicals during their breakdown, thereby poten-
tially reinforcing the harmful effects of oxidative stress
[20]. Dopamine quinone (DAQ) is generated from re-
leased DA in the striatum following in vivo or in vitro
rotenone pretreatment, but only under conditions of coin-
cident oxidative stress [16, 19, 20]. Inhibition of mitochon-
drial complex I by rotenone leads to energy depletion and
serves as a source of reactive oxygen species (ROS), caus-
ing oxidative damage at multiple target sites (lipid peroxi-
dation, protein and DNA damage, etc.). As a result, DA is
redistributed from vesicles and accumulates in the cytosol,
from where it is released and provides an additional
source of highly reactive free radicals by auto-oxidation or
by breakdown by MAO located at the outer surface of
mitochondria [21, 22]. Thus, DA is oxidized to the
electron-deficient, toxic DAQ, which reacts readily with
cellular nucleophiles, such as the sulfhydryl groups of
cysteinyl residues of peptides and proteins [23]. Those
drugs which simultaneously target mitochondrial dysfunc-
tion, oxidative stress and subsequent pathological dopa-
mine release may have disease-modifying potential in
addition to symptomatic improvement by the blockade of
self-amplifying circuits leading to ROS generation.
Recently, a novel series of (hetero)arylalkenylpropargy-
lamine compounds were synthesized, that demonstrate
highly potent MAO-B inhibitory activity with remark-
able selectivity over other types of amine oxidase en-
zymes [24]. In addition, a number of compounds among
this series displayed cytoprotective properties against 6-
hydroxidopamine (6-OHDA)-induced cell death in PC12
cells. However, culture-based cell survival assays repre-
sent oversimplified experimental systems, and they
might not reflect the complexity of in vivo systems.
Therefore, to extend these findings to in vivo conditions
and in order to identify their mechanism of action, in
the present study, six compounds were selected among
the most promising (hetero)arylalkenylpropargylamines
for further evaluation (Table 1). The selection of the
compounds was based (1) on their potency and selectiv-
ity to inhibit human recombinant MAO-B enzyme and
(2) on their protective properties against 6-OHDA in-
duced cell death in PC12 cells reported in our previous
study [24]. One compound (SZV558) was selected for
more detailed investigation: besides its excellent bio-
logical profile including neuroprotective actions in vitro,
it proved to be safe in high doses with no hERG and
mutagenic activities; moreover it possesses CNS drug-
like physicochemical properties with no significant viola-
tion of druglikeness scores including Rule-of-Five and
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Rule-of-Three based on in silico calculation with
QikProp (Schrodinger Suite).
We have examined the effect of the compounds on oxi-
dative stress induced pathological [3H]dopamine release,
subsequent [3H]DAQ formation and on tyrosine hydroxy-
lase (TH) immunoreactivity in the rotenone pretreated rat
striatum. Their effects were also evaluated on dopamine
depletion in MPTP- induced acute and subchronic mouse
models of Parkinson’s disease. However, a number of stud-
ies have indicated that the regimen of MPTP administra-
tion is fundamental to reproduce parkinsonian symptoms
and that its chronic administration induces a gradual and
persistent degeneration of nigrostriatal neurons associated
with motor deficit [25, 26]. Accordingly, chronic exposure
to low doses of MPTP over several weeks, in combination
with the clearance inhibitor probenecid, has been shown
to reproduce several aspects of the human disease and to
be a most suitable model for studying drugs with neuro-
protective potential [27–29].
On this basis, we have also evaluated the efficacy of
SZV558 compared with rasagiline in a chronic mouse
model of MPTP plus probenecid (MPTPp) in which a pro-
gressive development of parkinsonian symptoms, neurode-
generation, and neuroinflammation has been reported
[29]. Similarly to PD, this model has shown that a progres-
sive neurodegeneration is associated with a gradual devel-
opment of symptoms, from olfactory dysfunction to motor
impairment, providing a useful tool to test neuroprotective
therapies aimed at modifying disease progression [30].
Results
Effect of the compounds on oxidative stress-induced
pathological [3H]dopamine release in the rotenone
pretreated rat striatum
At first, we have evaluated the six selected compounds
in vitro and addressed the question, whether they coun-
teract the supraadditive effect of mitochondrial dysfunc-
tion and oxidative stress on subsequent pathological
[3H]dopamine efflux from superfused rat striatal slices.
After rotenone preincubation (10 μM, 60 min) and
60 min preperfusion the basal tritium efflux was 1.014 ±
0.08 % (Fig. 1a, n = 4) and remained relatively constant
throughout the sample collection period. Whereas a
switch to an identical medium did not change [3H]DA
efflux (control), oxidative stress, simulated by H2O2
(250 μM) perfusion elicited a remarkable increase in the
release of tritium (Fig. 1a). In line with literature data
[19], the selective MAO-B inhibitor, rasagiline (10 nM),
did not decrease oxidative stress-induced pathological
tritium release (Fig. 1a and c). In contrast, novel propar-
gylamine compounds (1 nM-100 nM) had a significant
inhibitory effect on the oxidative stress induced patho-
logical dopamine release in rat striatum slices in nano-
molar concentrations (Fig. 1a, c). In another set of
experiments, slices were subjected to electrical field
stimulation (EFS1, EFS2, 25 V, 1 msec, 2 Hz, 240 shocks)
twice to model physiological neuronal activity, and
SZV558 was administered 18 min before EFS2 and on-
wards (Fig. 1b). EFS elicited a rapid and reproducible ef-
flux of [3H]DA. However, SZV558 did not affect [3H]DA
release evoked by EFS, illustrating its differential effect
on pathological and physiological DA release (Fig. 1b).
To identify the formation of physiological and toxic dopa-
mine metabolites in the effluents, selected samples col-
lected under basal conditions and during the peak of the
effect of H2O2 were subjected to further HPLC analyses.
Separation of tritium label in the effluent revealed that in
samples collected under basal conditions, the tritium label
contained [3H]DA and its metabolites [3H]DOPAC,
[3H]HVA, and [3H]3-MT (Fig. 1d). HPLC analyses of the
samples, which were collected after the perfusion with
Table 1 The structural formulae of the test compounds used in
the study
Number Structure
Rasagiline mesylate
SZV-558
SZV-2220
SZV-2358
SZV2419
SZV-2435
SZV-2533
SZV-557
SZV-1680
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Fig. 1 (See legend on next page.)
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H2O2, showed that [
3H]DAQ and other metabolites of
dopamine, such as [3H]DOPAL and [3H]DOPET also ap-
peared in the effluent with a simultaneous decrease of
[3H]DA under these conditions, the proportion of which
decreased in these samples (50.66 ± 4.69 %, n = 6, and
Fig. 1e), when compared to the effluent collected under
resting conditions (65.64 ± 2.25 %, n = 6). SZV558 (100
nM) significantly reduced the formation of DAQ and
elevated the proportion of dopamine in the effluent
(Fig. 1e), indicating its protective effect against the
harmful interaction between mitochondrial dysfunc-
tion and oxidative stress.
As a readout of neuroprotective effect, TH immuno-
staining was also performed on tissue blocks containing
the substantia nigra pars compacta (SNc) after identical
treatments (Fig. 2). In line with expectation, substantially
less dopaminergic neurons stained for TH after rotenone
(ROT) treatment and a decreased volume of cell body
was also observable (P < 0.001 vs. CTRL, Fig. 2b, f ),
compared to control (CTRL) sections. There was no
further decrease in intensity of TH immunostaining
or difference in the shape of stained cell bodies in
samples treated with rotenone +H2O2 (Fig. 2c). Treat-
ment with rasagiline (100 nM) did not significantly change
the effect of rotenone +H2O2 on TH immunoreactivity
(P > 0.05 vs ROT+ H2O2, P < 0.01 vs CTRL, Fig. 2d, f ). In
contrast, in samples treated with SZV558, the number of
TH positive neurons was similar to the control sam-
ple, demonstrating the rescuing effect of SZV558 on
dopaminergic neurons against the toxic compound
rotenone (P < 0.001 vs. ROT, P > 0.05 vs. CTRL and
rotenone + H2O2, P < 0.01 vs. rasagiline, Fig. 2e, f ).
The protective effect of the compounds in acute
MPTP-induced striatal dopamine depletion and motor
deficit in mice
Next, we evaluated the effect of test compounds on the
level of endogenous DA and its metabolites by HPLC
analyses in in vivo murine PD models. The effect of two
compounds (SZV558 and SZV2220), displaying high po-
tency at both rodent and human MAO-B [24] were also
examined on MPTP/MPP+ levels and on motor func-
tion. Whilst all the other compounds were used as a
single i.p. pretreatment in 10 mg/kg dose prior to MPTP
regimen, in case of SZV558, the most promising com-
pound according to previous in vitro data, dose-
dependence, per os route of administration and duration
of action were also tested.
To study the effect of the compounds under in vivo con-
ditions, at first, we took advantage a widely used acute
MPTP protocol (4x20 mg/kg i.p. 2 h apart), and test com-
pounds were administered 18 h before the start of MPTP
treatment. Animals were sacrificed 72 h after the last
MPTP dose and the amount of MPTP and MPP+ in striatal
samples were analyzed by HPLC-UV (Fig. 3a-b). The
majority of MPTP has already been converted to MPP+
at this time point, (Fig. 3b, 25.29 ± 6.65 pmol/mg pro-
tein, n = 8), although MPTP was still clearly detectable
(5.87 ± 2.19 pmol/mg protein, n = 8). Although there
was a tendency of reduction of both MPTP and MPP+
in case of SZV558, no significant difference were de-
tected in their amount in mice that have been pre-
treated with SZV2220 or SZV558 18 h before the start
of MPTP treatment when compared to vehicle treated
animals (Fig. 3b).
To assess whether the compounds are able to protect
against the effects of MPTP and preserve the functional-
ity of nigrostriatal dopaminergic pathways, endogenous
dopamine contents were analyzed in the striatum by
HPLC. MPTP treatment on mice pretreated with saline,
elicited a loss of approximately 85 % of endogenous
dopamine content in the striatum, accompanied by a de-
crease in the survival of the animals (Fig. 4a, b). In con-
trast, mice pretreated with test compounds, (10 mg/
kg i.p. each) were in overall good health following MPTP
treatment, and none of the drugs produced any obvious
untoward behavioral alteration at the dose used. More-
over, the test compounds significantly protected against
the effect of in vivo MPTP treatment on the depletion of
striatal dopamine content i.e. against the hallmark fea-
ture of PD (Fig. 4a) and also completely restored the sur-
vival of animals during the course of the experiment
(Fig. 4b). The effect of SZV558 was dose-dependent and
displayed a tendency of saturation at the 10 mg/kg dose
(Fig. 4c). SZV558 was also active using per os application
(20 mg/kg, Fig. 4d) and completely restored the
(See figure on previous page.)
Fig. 1 Effect of test compounds on oxidative stress induced pathological tritium release after rotenone treatment (a, c); on electrical field stimulation (EFS)
evoked [3H]DA release (b) and on the tritium composition in the effluent (d, e) in rat striatal slices. a, b. Oxidative stress was mimicked by the perfusion of
H2O2 (250 μM), as indicated by the horizontal bar on a. Control slices were perfused identically with Krebs’ solution, but without H2O2. Test compounds or
their vehicle (CTRL) were administered 18 min before the perfusion with H2O2 and onwards. b. SZV558 or its vehicle (CTRL) was administered 18 min
before EFS2 and onwards. The release of [3H]DA and its tritiated metabolites is expressed as fractional release (%). N= 4-8 independent experiment/group.
c When the effects of drugs were compared on H2O2 evoked tritium release, the net release evoked by H2O2 calculated by the area-under-the-curve
method was taken into account. N= 4-8 independent experiment/group. Symbols represent significant changes from control slices (+++P< 0.001), and
H2O2 treated slices (*P< 0.05, **P< 0.01, ***P< 0.001), respectively. Statistical analysis: one-way ANOVA followed by the Tukey test. d, e The samples labelled
by arrows (R1, S1) on a were analyzed by HPLC to identify the composition of the tritium label. The composition of the tritium efflux is expressed as
percentage of the total tritium efflux. N= 6-8
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Fig. 2 Tyrosine hydroxylase (TH) immunostaining in rat SNc after in vitro rotenone (ROT) (b) rotenone +H2O2 (c), rotenone +H2O2 + rasagiline (RAS)
(d) and rotenone +H2O2 + SZV558 treatment (e). The caudal part of the brain containing the SNc was prepared from rats and then the experiment was
continued according to the protocol described in the Methods. After the experiment, 40 μm coronal vibratomic midbrain sections were prepared and
processed for TH immunostaining. a Immuno-DAB staining for TH on control tissue sections. Immunoreactivity is seen in the cell body and processes of
dopaminergic and noradrenergic neurons. b Due to rotenone treatment both the number of immunolabelled neurons and the intensity of staining is
substantially decreased. The cell bodies of stained neurons are smaller than in the control sample. c Weak immunostaining shows some TH-expressing
neurons on the rotenone +H2O2treated section. d TH immunoreactivity in SNc after rotenone +H2O2 + rasagiline treatment. e Intensity of DAB immuno-
staining for TH on the SN area looks similar to the control tissue after rotenone +H2O2 + SZV558 treatment of the tissue. Arrows show cell body of dopa-
minergic/noradrenergic neurons. Original magnification: 20X, bar: 100 μm f. Quantification of the TH immunostaining. Digitalization was performed by
means of a Pannoramic P250 scanner (3DHISTECH, Budapest, Hungary) using 9 optical layer with a resolution of 0.11 μm/pixel. Pictures were taken at five
representative areas in each of samples at 40× magnifications. The stained cells were counted manually, marked with a marker counter function of the
Pannoramic Viewer 1.15.4 digital slide viewer software application provided by 3DHISTECH, Budapest, Hungary and expressed as number/mm2 (nr/mm2).
Statistical analysis: one-way ANOVA followed by the Tukey test. **P< 0.01, ***P< 0.001, as indicated by the horizontal bars. N= 4–5 /group
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dopamine content of the striatum above the level of
mice treated only with saline but not MPTP (Fig. 4d). At
this dose, SZV558 was significantly more effective than
rasagiline (P < 0.001).
To get a further insight on the action of test com-
pounds, their effects were also examined on the level of
dopamine metabolites in the striatum. In line with litera-
ture data [31], MPTP treatment tended to reduce the
level of dopamine metabolites DOPAC and HVA (Fig. 4e
and f), although this was only statistically significant in
case of HVA (Fig. 4f ). Rasagiline (10 mg/kg i.p.), did not
restore the level of metabolites in the presence of MPTP,
but further decreased the level of DOPAC and HVA. In
contrast, SZV2220 and SZV2533 increased DOPAC
levels, (Fig. 4e), and HVA levels were also restored by
SZV2220 (Fig. 4f ).
To examine motor function, two widely used tests, i.e.
the open field and the rotarod test were used. Deteriorated
motor function in MPTP-treated animals was restored by
SZV2220 and SZV558 (Fig. 4g and h). 2 h following the
final MPTP treatment, the basal locomotor activity of
mice was minimal, i.e. they displayed akinesia (Fig. 4g). In
contrast, mice pretreated with SZV558 and SZV2220
(10 mg/kg i.p. each) showed a profound increase in basal
locomotor activity, even at this early time point (Fig. 4g).
In the rotarod test, mice treated with MPTP displayed a
time-dependent decrease in motor performance, compared
to values measured before MPTP treatment (Fig. 4h). This
progressive decline in performance was almost completely
prevented by both SZV558 and SZV2220 and was main-
tained up to 24 h after drug injection (Fig. 4h). Within the
time frame examined, the effects of test compounds on
motor function were comparable to that of rasagiline.
In order to estimate their duration of action, SZV558
and rasagiline were applied in a single dose (10 mg/
kg i.p.) 2 h, or 42 h before the first dose of MPTP in an-
other set of experiment (Additional file 1: Table S1). A
slight protective effect against dopamine depletion
A
B C
Fig. 3 Effect of SZV compounds on the level of MPTP and MPP+ after an acute (b) and subchronic (c) MPTP treatment protocol. a Representative
chromatogram generated by UV detection at 253 nm, showing MPTP (1) and MPP+ (2). Theophylline was used as internal standard (IS). b Animals
were pre-treated with test compounds or their vehicle (VEH) i.p. 18 h before the first dose of MPTP; then treated with MPTP 4×20 mg/kg i.p. 2 h
apart. MPTP and MPP+ levels were analyzed in striatum samples obtained 72 h after the last dose of MPTP c. Mice were treated with MPTP (30 mg/
kg i.p. daily) for 5 days and then, for 21 days with the test compounds or their vehicle (VEH) i.p. and sacrificed 1 h after the last treatment. MPTP and
MPP+ were analyzed by HPLC and expressed as pmol/mg protein. Note that the y scale in b and c is different. N = 6-8/group. Symbols
represent significant changes from vehicle treated rats (*P < 0.05). Statistical analysis: one-way ANOVA followed by the Tukey test
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elicited by MPTP was already detected 2 h after injec-
tion of SZV558, although this effect was not statistically
significant. The maximum of the effect of SZV558 was
obtained 18 h after application. The effect of SZV558
then declined and a tendency of protection was still de-
tected 42 h after SZV558 administration. These data in-
dicate the irreversible inhibition of the MAO-B enzyme
by SZV558; rasagiline, which is also an irreversible in-
hibitor of the MAO-B enzyme, had a similar duration of
action (Additional file 1: Table S1). Among SZV557 and
SZV1680, the two major potential metabolites of
SZV558, SZV557 displayed partial activity at the MAO-
B enzyme, whereas SZV1680 proved to be much less ac-
tive at both MAO isoforms [24]. In the in vivo MPTP
model, SZV557 was partly active, whilst SZV1680
remained completely inactive in the restoration of en-
dogenous dopamine content of the striatum, when
added 18 h before the first MPTP injection. Regard-
ing survival, SZV557 was fully active, whilst SZV1680
only marginally affected the survival of the animals.
This finding indicates that the propargyl-moiety of
the compounds is instrumental for their antiparkinso-
nian effect.
The protective effect of SZV558 in subchronic MPTP-induced
striatal dopamine depletion
Next, a more complex, delayed rodent MPTP protocol
[32, 33] was utilized to examine whether the protective
effect of the compounds (1) is entirely due to their
MAO-B inhibitory action and (2) is prolonged for a long
time and is extended to apoptotic neuronal death char-
acteristic of human PD. Using the protocol described by
Tatton and Kish [32, 33], mice were treated daily with
MPTP (30 mg/kg i.p) for 5 consecutive days and test
compounds or their vehicle were delivered for 21 days
only after then, when the majority of MPTP is expected to
be converted to the toxic MPP+ [33, 34]. Using this proto-
col, MPTP and MPP+ detected in these samples was less
than 10 % detected 72 h after the last MPTP dose in the
acute model, although still present, with a low MPTP/
MPP+ ratio (<5 %, MPTP: 0.08 ± 0.01 pmol/ mg protein,
n = 8, MPP+: 1.99 ± 0.10 pmol/mg protein, n = 8) (Fig. 3c).
Once again, test compounds, i.e., SZV558 and SZV2220
did not decrease the level of MPP+ detected in the sam-
ples (Fig. 3c), MPP+ levels were significantly higher in
samples collected from mice treated with the test com-
pounds than in mice treated with vehicle.
Application of MPTP treatment using this method
resulted in a 60 % reduction of endogenous dopamine
content in the striatum, when compared to saline
treatment (Fig. 5). SZV558, but not the reference
compound rasagiline (10 mg/kg/day i.p. each, for
21 days), significantly restored the endogenous dopa-
mine content (Fig. 5).
Fig. 5 The effects of SZV558, SZV2220 and rasagiline (10 mg/kg i.p
for 21 days each) on MPTP treated mice striatum using a subchronic
(Tatton-Kish) model of PD. The MPTP group received vehicle treatment
for the same period after the MPTP treatment. Dopamine content is
expressed as pmol/mg protein. Symbols represent significant changes
from saline treated (+++P < 0.001), MPTP treated (***P < 0.001) and
rasagiline treated animals, (#P < 0.05), respectively. Statistical analysis:
one-way ANOVA followed by the Tukey test. Number of independent
experiments: 8-12/group
(See figure on previous page.)
Fig. 4 Effect of SZV compounds on endogenous dopamine content in the striatum (a, c, d); on the survival of mice (b); on endogenous dopamine
metabolite (DOPAC, HVA) levels (e, f); on the basal locomotor activity (g) and on motor coordination (h) after in vivo MPTP treatment. a Effect of test
compounds and rasagiline (10 mg/kg i.p. each) on endogenous dopamine level in the striatum; b on the survival of the animals. Survival is expressed as
percentage of the initial number of animals. c Dose-dependent effect of SZV558 (0.1-10 mg/kg i.p.) on endogenous dopamine content in the striatum.
d Effect of SZV558 and rasagiline (20 mg/kg per os each) on endogenous dopamine content in the striatum. a, c, d Dopamine content is expressed as
pmol/mg protein. e, f Effect of SZV compounds (10 mg/kg i.p.) on endogenous dopamine metabolite (DOPAC, HVA) levels. Metabolite levels are
expressed as pmol/mg protein. g Effect of SZV compounds (10 mg/kg i.p.) on the basal locomotor activity, measured in the open field
test. Locomotion is expressed as the distance traveled during the whole 30 min test period. a-g Symbols represent significant changes
from saline treated (++P < 0.01, +++P < 0.001), MPTP treated (**P < 0.01, ***P < 0.001) and rasagiline (10 mg/kg) treated (##P < 0.05, ###P < 0.001) animals,
respectively. Statistical analysis: one-way ANOVA followed by the Tukey test, except b: log rank test. Number of independent experiments: 5-12/group.
h Effect of SZV compounds (10 mg/kg i.p.) on the motor performance measured on the rotarod test. The time elapsed until the falling of the mice
was expressed in sec. Symbols represent significant changes from respective pretreatment values (**P < 0.01). Statistical analysis: one-way ANOVA
followed by the Dunnett test
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Effect of SZV558 in a chronic MPTPp induced mouse
model of PD
Since PD is a chronic neurodegenerative disease, SZV558
was compared with rasagiline in a chronic mouse model
of MPTP plus probenecid (MPTPp) characterized by the
progressive development of parkinsonian symptoms, neu-
rodegeneration, and neuroinflammation [29]. To investi-
gate whether the impairments of motor performance and
olfactory dysfunction induced by MPTPp were reverted
by SZV558, we evaluated motor performance and olfac-
tory function with the beam-walking test, the inverted grid
test, the motility test, and the pellet retrieval olfactory test.
Moreover, the neuroprotective efficacy of SZV558 on
dopaminergic neuron degeneration was assessed in the
striatum and the SN pars compacta (SNc) by TH
immunohistochemistry.
Changes in spontaneous motor activity: motility test
To evaluate the modification of the spontaneous motor
activity induced by the treatment, the total activity and
the ambulatory activity were evaluated through the mo-
tility test before the MPTPp treatment and 1 day after
the last MPTPp administration. We observed no signifi-
cant changes for total activity (Table 2) and ambulatory
activity (Table 2) after MPTPp administration. Moreover,
in animals treated with MPTPp compared with vehicle
and MPTPp plus SZV558 or rasagiline groups, the one-
way ANOVA did not indicate a significant effect of treat-
ment in the ambulatory activity.
Effect of motor impairment induced by MPTPp:
beam-walking test
The number of steps and errors were recorded for each
animal 2 days after the 10th MPTPp administration, in
order to evaluate, respectively, the motor performance
and coordination. Despite, the analysis of the time to
traverse the beam did not show any difference between
the four groups (data not shown). The analysis of the
number of steps showed an increase in the MPTPp group.
The post hoc test (Newman-Keuls) showed that treatment
with SZV558 or rasagiline prevented the impairment in-
duced by MPTPp (Fig. 6a).
Analysis of the total errors showed that MPTPp ad-
ministration induced a significant increase in total errors
compared with vehicle, demonstrating motor function
impairment (Fig. 6b). Motor function improvement,
demonstrated by the decrease in total errors, was ob-
served in the groups treated with SZV558 or rasagiline
compared with the MPTPp group, as indicated in the
post hoc test.
Effect of grasp-strength evaluation: inverted grid test
The inverted grid test was used to assess forepaw use,
especially related to distal musculature and digit manipu-
lations. This test was done 2 days after the end of treat-
ment. No significant changes with either MPTPp or
rasagiline were observed, indicating that the mice did not
have any distal musculature deficit (Fig. 6c).
Effect of SZV558 on olfactory deficit induced by MPTPp
To reveal any effect of the compounds on olfactory def-
icit, elicited by MPTPp, mice were evaluated for olfac-
tory function 3 days after the end of treatment, through
the retrieval time of a buried smelling pellet.
The results of olfactory test showed an increase of re-
trieval time of a buried smelling pellet, demonstrating an
olfactory deficit, in the MPTPp group. In mice treated
with MPTPp plus SZV558 or rasagiline, a decrease in re-
trieval time was observed compared with the MPTPp
group (Fig. 6d).
TH immunohistochemistry and Nissl Staining in the SNc and
striatum
Next, to evaluate the effect of test compounds on
dopaminergic cell death, TH immunohistochemistry and
Nissl Staining were performed in the SNc and striatum.
MPTPp induced a significant loss of TH-positive cells in
the SNc, as measured by TH immunoreactivity (Fig. 7a).
Analysis of Nissl-positive nigral neurons showed the neur-
onal death of MPTPp treated mice compared to vehicle,
confirming the dopaminergic neuron degeneration
induced by MPTPp. The post hoc analysis (Tukey’s test)
of TH immunoreactivity showed that the combined
Table 2 Motility test pre- and post-chronic MPTPp treatment
TOTAL ACTIVITY
Pre-treatment Post-treatment
Mean SEM Mean SEM
Vehicle 11503.75 983.49 8737.50 1651.77
MPTPp 5803.80 1162.18 6587 771.63
MPTPp + SZV558 9063.14 1055.95 7904.85 982.36
MPTPp + Rasagiline 9941.57 1055.57 8867.85 1214.24
LOCOMOTOR ACTIVITY
Vehicle 8727 983.49 3690.25 1651.77
MPTPp 4004.60 916.64 2773.40 343.84
MPTPp + SZV558 6929.85 791.63 3415.86 463.68
MPTPp + Rasagiline 7497 928.82 3938 639.83
Motor activity was measured 2 days before the first MPTPp administration and
1 day after the last MPTPp administration. Values are expressed
as mean ± SEM
Data were statistically compared with one-way ANOVA, followed by the New-
man–Keuls post hoc test
Number of independent experiments: 4–7/group
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treatment with MPTPp plus SZV558 or rasagiline pre-
vented the loss of dopaminergic neurons in the SNc, ob-
served in the animals treated with MPTPp alone (Fig. 7b).
The cresyl violet staining (Fig. 7c) confirmed the loss and
the recovery in number of neurons in the SNc in MPTPp
and MPTPp plus SZV558 or rasagiline treated mice
(Fig. 7c).
The loss of TH-positive fibers in the striatum of mice
treated with MPTPp confirmed dopaminergic neuron
degeneration (Fig. 7d). Both SZV558 and rasagiline pre-
vented neurodegeneration in the striatum compared
with the MPTPp group, as shown by the post hoc ana-
lysis (Tukey’s test) of TH-positive fibers in the striatum.
Discussion
Parkinson’s disease (PD) is a chronic neurodegenerative
disease, characterized by motor and non-motor symp-
toms, which progressively diminish quality of life and
the ability to work, and lead to permanent disability. Al-
though these symptoms can be improved using
currently available dopamine replacement strategies,
treatments that provide neuroprotection and/or disease-
modifying effects remain an urgent unmet clinical need
[9].
Among in vivo rodent animal models of PD, toxin-
induced models (e.g. MPTP, rotenone, 6-OHDA) elicit
substantial and reproducible degeneration of catechol-
aminergic cells and are therefore widely used for test-
ing protective therapeutic interventions [35, 36]. In
the present study, the effects of six representatives of
a novel series of propargylamine compounds and, as a
reference compound, rasagiline were evaluated in sev-
eral different toxin-induced PD models. In addition,
one compound (SZV558) was investigated in more
details to identify its impact on the formation of toxic
[3H]DAQ and on the survival of substantia nigra
dopaminergic neurons after in vitro rotenone pre-
treatment, and to be the subject of a more detailed
pharmacological characterization in the in vivo acute
MPTP model and in a chronic MPTP model. In our
previous study SZV558 inhibited both rat and human
MAO-B with high potency (IC50rat: 50 nM, IC50human:
60 nM) and reasonable selectivity (human MAOA/B
selectivity ratio: 58), and elicited a 66 % increase in
the survival of PC12 cells treated with 6-OHDA [24].
In cases of test compounds, a consistent protective
effect was detected in all models, which was quantita-
tively and in some cases, qualitatively superior to rasagi-
line. Moreover, the protective effect was manifested in
various forms of indicators from dopamine depletion to
animal behavior, without the appearance of any detect-
able detrimental side effects.
Fig. 6 The effect of SZV558 on the behavior in the chronic MPTPp induced PD in mice. Adult mice were treated with vehicle plus probenecid, or
MPTP (25 mg/kg i.p.) plus probenecid (100 mg/kg i.p.), administered 30 min before each MPTPp, twice a week for 5 weeks, alone, or in the presence of
the SZV558 (1 mg/kg i.p.) or rasagiline (1 mg/kg i.p.) administered 18 h before each MPTPp administration. a-b Beam-walking test. To evaluate the
number of steps (a) and the total errors (b), the mice were videotaped for a total of five trials, 2 days after the 10th MPTPp administration. The number
of steps and the number of errors were calculated across all five trials and averaged for each group. * P < 0.05 compared with vehicle, #
P < 0.05 compared with MPTPp. c Inverted grid test. To assess skilled forepaw use, the latency time of falling down was measured 2 days after the 10th
MPTPp administration. d Olfactory test. To evaluate the olfactory deficit, the retrieval time of a buried smelling pellet was measured 3 days after the
10th MPTPp administration. * P < 0.05 compared with MPTPp. Values are expressed as mean ± SEM. Data were statistically compared with one-way
ANOVA, followed by the Newman-Keuls post hoc test. N: 4–7/group
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As a potential mechanism of action, all compounds
inhibited oxidative stress-induced pathological dopamine
release in the rotenone treated rat striatum slices (Fig. 8).
In our previous studies we established that mito-
chondrial dysfunction and oxidative stress have a
supraadditive impact on the pathological, cytoplasmic
accumulation of dopamine and its subsequent release
[16, 20]. Moreover, in dopaminergic neurons, mono-
amines and their metabolites provide an additional
source of highly reactive free radicals during their
breakdown by MAO or auto-oxidation, thereby potentially
reinforcing the harmful effects of oxidative stress [37]. In
this study, we have confirmed these results and revealed
that test compounds inhibited this pathological [3H]DA ef-
flux, without affecting [3H]DA release induced by the low
frequency electrical stimulation modelling physiological
neuronal activity. Test compounds were effective in a low
concentration, in contrast to rasagiline, which remained in-
effective in this respect. Because both rasagiline and the test
compounds potently inhibit MAO-B, these findings
Fig. 7 Immunoreactivity for TH in the SNc and in the striatum. Mice were treated with MPTPp alone or in the presence of SZV558 or rasagiline,
and sacrificed 3 days after the 10th MPTPp administration. Coronal sections were processed for TH immunostaining as described in the Materials
and Methods. Representative coronal sections of SNc immunostained for TH show the TH positive neuronal reduction induced by MPTP treatment
(a). The graphs show the number of TH immunoreactive cells (b) and of Nissl-stained cells (c) in the SNc, expressed as a percentage with respect to
vehicle-treated mice. SZV558 and rasagiline prevented the loss of TH-positive neurons in the SNc, as compared with the animals treated with MPTPp.
Representative coronal sections of striatum immunostained for TH at 5× magnification (d). The graph shows the mean density of gray value of TH
expressed as a percentage with respect to vehicle-treated mice (e). The TH density reduction confirms the neurodegeneration induced by MPTP. The
two compounds prevent the loss of TH positive fiber induced by MPTPp. Values are expressed as mean ± SEM. * P < 0.05 compared with vehicle. #
P < 0.05 compared with MPTPp. Data were statistically compared with one-way ANOVA, followed by Tukey’s post hoc test. N: 4–7/group
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indicate that the putatively protective action of the test
compounds is partly independent from inhibition of MAO-
B.
In case of SZV558, we have also analysed the tritium
composition under resting conditions and during the peak
of the effect of H2O2. Whilst in the effluent collected
under basal conditions [3H]DA is partly converted to
major metabolites of dopamine i.e. [3H]DOPAC, [3H]3-
MT and [3H]HVA, in the effluent collected under the
action of H2O2, other metabolites, such as [
3H]DOPET
and [3H]DOPAL also appeared. Moreover, the toxic
[3H]DAQ is also formed under these conditions but
only in the case of precedent mitochondrial dysfunc-
tion, as we have shown previously [16, 20]. A peculiar
action of SZV558 was the inhibition of the formation of
[3H]DAQ, with the preservation of a higher proportion
of [3H]DA in the effluent. The harmful effect of DAQ is
well documented as an effector molecule of dopamin-
ergic neuron-specific cytotoxicity [38, 39]. In general,
the targets of catechol quinones are cysteine residues of
peptides or proteins, and quinones conjugate with
their sulfhydryl groups resulting in the formation of
5-cysteinyl-catechols. This covalent modification can
irreversibly compromise protein function and is there-
fore cytotoxic [40]. DAQ and its downstream metabo-
lites reduce mitochondrial function and open the
mitochondrial permeability transition pore [41–43].
DAQ also inhibits the function of endogenous ROS
scavenging enzymes such as glutathione peroxidase
[44] and superoxide dismutase [45]. In addition DAQ
inhibits proteasomal activity [46] and inactivates func-
tional proteins of dopaminergic neurons such as TH
[47, 48], dopamine transporter [49] and α-synuclein
[50]. SZV558 was able to decrease the formation of
[3H]DAQ, with the preservation of more [3H]DA in
the effluent, therefore one can assume that it specific-
ally interacts with factors increasing the vulnerability
of dopaminergic neurons.
As a histological marker of ongoing neurodegeneration
in response to in vitro rotenone treatment, TH immuno-
staining was examined in the SNc. Our findings revealed
that SZV558 not only alleviated DAQ formation in the
striatum but was also able to rescue SNc dopaminergic
neurons from the toxic effect of rotenone as shown
by the restoration of TH immunostaining in tissue
samples following SZV558 treatment after rotenone
Fig. 8 Schematic drawing illustrating the potential mechanism of action of novel (hetero)arylalkenylpropargylamines (SZV) in the striatum. Mitochondrial
deficit, caused by the mitochondrial complex I inhibitor rotenone leads to reactive oxygen species (ROS) generation. Coincident or subsequent oxidative
stress, mimicked in our experiments by H2O2 leads to redistribution of DA from synaptic vesicles to cytoplasm, where it is converted to toxic dopamine
quinone (DAQ). DA is then released to the extracellular space. DAQ targets the cysteinyl residues of peptides and proteins and compromise
cellular function at multiple target sites and aggravates mitochondrial deficit. SZV compounds 1. inhibit MAO-B enzyme, and thereby
increase the biological availability of dopamine; 2. in addition, they prevent oxidative stress induced pathological DA efflux and its further
formation to toxic DAQ, independent from the inhibition of MAO-B, but do not have direct antioxidant property and do not influence
physiological neuronal activity induced DA release, mimicked by electrical field stimulation (EFS)
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preincubation. Interestingly, H2O2 treatment did not
exacerbate the neurotoxic effect of rotenone on dopa-
minergic cell bodies in the SNc, which implies that the
primary site of the pathological interaction of mitochon-
drial deficit with H2O2 is at the level of dopaminergic
terminals in the striatum. Moreover, because the
compounds lack direct antioxidant activity (C.L.L. Chai,
unpublished observation), it appears that inhibition of
self-amplifying pathological cytoplasmic DA efflux and
DAQ formation at the striatal nerve terminals could
prevent subsequent oxidative damage in the substantia
nigra indirectly. This feature could also be beneficial
during the early stages of neurodegeneration.
The MPTP model is used widely for preclinical in vivo
assessment of anti-parkinsonian effects, due to its high
reproducibility and disease-related pathological features
[35, 51–53]. MPTP is first taken up by astrocytes and
converted there to the toxic metabolite 1-methyl-4-phe-
nylpyridinium (MPP+) by the MAO enzyme. MPP+ is
then released and selectively taken up to the dopamin-
ergic nerve terminals by the dopamine transporters and
causes the oxidative damage of dopaminergic neurons
[36]. When degeneration of the nigrostriatal dopamin-
ergic pathway was examined in an acute MPTP-induced
in vivo PD model in mice, a consistent protective effect
was detected by the test compounds, both in terms of
dopamine depletion, survival rate and motor function. We
have chosen the compound SZV558 for a more detailed
characterization and its effect was dose-dependent, with a
significant effect detected in lower, 1 mg/kg dose in line
with its nanomolar potency to inhibit MAO-B enzyme.
Moreover, its protection was more efficient than rasagiline
using oral route of application, indicating that its pharma-
cokinetic properties are suitable for per os treatment. Al-
though not all compounds displayed this effect, SZV2220
and SZV2533 had a preferable effect on the level of en-
dogenous dopamine metabolites. In case of rasagiline, the
level of DOPAC and HVA remained at a low level after
MPTP treatment, which is probably explained by the
complete inhibition of MAO-A and MAO-B at this rela-
tively high dose, which prevented the further metabolism
of dopamine [54]. In contrast, SZV2220 and SZV2533 re-
stored the level of dopamine metabolites which indicates
an enhanced turnover rate and functionality of surviving
dopaminergic nerve terminals. As for the behavioral read-
out, the effect of SZV compounds was comparable to that
of rasagiline.
The acute MPTP model used in the previous exper-
iments represents a fast and reliable experimental
method to elicit non-apoptotic degeneration of the
nigrostriatal dopaminergic pathway affected in PD.
However, the progress of the neurodegeneration in
human PD patients is initially slow and gradual and
take place in both apoptotic and non-apoptotic way.
Moreover, because MPTP is converted to the toxic
metabolite MPP+ by the MAO-B enzyme, the in vivo
protective effect of the compounds in the acute
model might be simply explained by the inhibition of
MPP+ formation, but not a genuine neuroprotective
action. To clarify this issue, we have analyzed MPTP
and MPP+ levels in the striatum samples derived from
mice subject to pre-treatment with test compounds or
saline. As expected, the majority of MPTP has already
been converted to MPP+ at this time point, and al-
though MPTP was still detectable, it remained at a
low level. There was no significant difference in MPP+
levels in mice that have been pretreated with SZV2220 or
SZV558 18 h before the start of MPTP treatment, when
compared to vehicle treated animals. This finding indi-
cates that the compounds had a negligible effect on the
MPTP/MPP+ ratio under our experimental conditions.
Nevertheless we cannot entirely exclude that at an earlier
time point after MPTP addition (<72 h), the compounds
delayed the formation of MPP+ as it is postulated that a
substantial part of MPTP is converted to MPP+ by MAO-
B enzyme [32, 55].
Therefore, two test compounds, SZV558 and SZV2220
were examined in another rodent MPTP model, i.e. in
the Tatton-Kish model [32, 33]. The protocol used by this
model results in a prolonged, apoptotic degeneration of
SNc neurons lasting about 3 weeks after a short course of
daily MPTP administration and the putative protective
agents are added only after MPTP administration. Conse-
quently, a protective effect clearly independent from the
disruption of MPTP uptake and metabolism by MAO-B
inhibition could be revealed. Using this protocol, a less se-
vere, but still significant depletion of striatal endogenous
dopamine content was found after MPTP treatment in
good agreement with previous studies [33]. SZV558 was
protective and more efficacious than rasagiline against the
depletion of dopamine, even after the administration of
MPTP, i.e. when almost all MPTP is already converted to
the toxic metabolite MPP+ by the MAO-B enzyme, as
confirmed by HPLC analyses. This observation indicates
that SZV558 has a protective action independent from the
inhibition of MAO-B enzyme. To further support this
assumption, SZV2220, which is a more potent but less se-
lective inhibitor of MAO-B than SZV558 [24], was less ef-
fective in this experimental paradigm.
In the acute and subchronic in vivo MPTP models we
have regarded the preservation of the dopamine con-
tent by the test compounds as an indicator of increased
survival of dopaminergic neurons. To prove their effi-
cacy on dopaminergic cell death in vivo, we have also
evaluated the neuroprotective effect of SZV558 against
the loss of tyrosine hydroxylase immunoreactivity in
the SNc and against PD-like motor symptoms in a
chronic MPTPp model. This latest model, differently
Baranyi et al. Molecular Neurodegeneration  (2016) 11:6 Page 14 of 21
from acute MPTP treatments that induce a rapid de-
generation of dopaminergic nigrostriatal neurons, in-
duces a more progressive degeneration, with neurons
continuing to die after completion of toxin administra-
tion [27]. Moreover, when MPTP is co-administered
with probenecid, which retards the renal and central
nervous systems’ clearance of the toxic metabolites of
MPTP, the degeneration of dopaminergic neurons takes
place over a period of 5–8 weeks. This chronic regimen
induces apoptosis, without mortality of mice which sur-
vive in a healthy state to the treatment, very important
for the subsequent behavioral testing. Moreover, the
chronic treatment induces olfactory deficit, one of the
symptoms that characterizes the early as well as late
stages of PD. Progression in a model with MPTP is a
very important requirement since it allows the study of
the efficacy of neuroprotective drugs during the pro-
gressive dopaminergic neurodegeneration, reproducing
human pathology more closely. The chronic model uti-
lized in this study has been well characterized and was
validated for utilization in a protocol of drug-induced
neuroprotection [30].
The beam-walking test showed that MPTPp increases
the number of steps and errors, indicating an impair-
ment of gait. It is interesting to note that the beam-
walking test strictly reflects the deficits that characterize
PD, such as slowness of movements, indicated by the
increased number of steps to traverse the length of the
beam, together with an unstable gait, indicated by the
number of errors [56]. SZV558, similarly to rasagiline,
counteracts the slowness of movement, together with
the unstable gait induced by chronic MPTPp. In con-
trast, no impairment after chronic MPTPp was ob-
served in the grip test, indicating that limb strength
was not impaired by the chronic regimen of MPTPp
administration and no modifications were produced by
either SZV558 or rasagiline. Not surprisingly, no differ-
ences were observed in locomotor activity and total
motility after chronic MPTPp, as adaptive changes in
motility are consistently observed when the DA neuron
lesion does not exceed 70–80 % [27, 57]. Moreover,
SZV558 counteracted the olfactory deficit induced by
chronic MPTPp as measured by the decreasing pellet
retrieval time.
The rescue of neurodegeneration was not only indicated
by the positive results obtained in the above-mentioned
behavioral tests, but also by the immunohistochemical re-
sults that showed that dopaminergic neurodegeneration,
evaluated through TH immunohistochemistry, was res-
cued by SZV558. The drug, similarly to rasagiline, com-
pletely counteracted the decrease in TH-positive neurons
and terminals observed after chronic MPTPp in the SNc
and striatum, respectively. Therefore, the results showed a
strict association between behavioral and biochemical
markers of dopaminergic neurodegeneration. In addition,
we used a Nissl stain in order to verify the real death of
dopaminergic neurons in the SNc. The results of that
analysis confirmed that chronic MPTPp caused a de-
generation of dopaminergic cells and that SZV558
produces neuroprotection.
Conclusions
In conclusion, the novel propargylamines are protective
in all in vitro and in vivo models of PD used. Therefore,
simultaneous inhibition of MAO-B and oxidative stress-
induced pathological dopamine release seems to be a
plausible strategy to combat PD (Fig. 8), and to our
knowledge this is the first report on compounds specific-
ally interacting with these mechanisms. In addition, neu-
roprotection by SZV558 is demonstrated in an in vivo
chronic model of PD, confirming the therapeutic poten-
tial of this compound on neurodegenerative disease.
PD is a multifactorial disease and several risk factors
contribute to the vulnerability of DA neurons [58],
therefore, SZV558 by affecting multiple targets, may,
through these differentiated mechanisms have a more fa-
vorable action than other MAO-B inhibitors as neuro-
protective agent in the therapy of PD.
Methods
Animals
All studies were conducted in compliance with the
Directive 2010/63/EU and ARRIVE guidelines and
were approved by the local Animal Care Committee
of the Institute of Experimental Medicine (Budapest,
Hungary, Permission No: 22.1/3671/003/2008) or by
the Ethical Committee of the University of Cagliari.
Animals were kept under standard laboratory condi-
tions (12 h light/12 h dark cycle) with food and water
ad libitum. All efforts were made to minimize animals
suffering and reduce the number of animals used.
[3H]dopamine release experiments in rat striatal slices
The [3H]dopamine ([3H]DA) release experiments were
performed as described in our previous studies [18, 19]:
male Wistar rats (180–220 g, obtained from the local
animal house) were decapitated under light CO2
anesthesia and the brain quickly removed into ice-cold
Krebs’ solution. The striatum was dissected and sliced
into 400 μm sections with a McIlwain tissue chopper.
Striatum slices then were pretreated with rotenone
(10 μM, Sigma) for 60 min, and subsequently incubated
in 1 ml of Krebs’ solution containing 5 μCi [3H]DA
(spec. activity: 60 Ci/mmol, ARC, Saint Louis, MO,
USA) for 45 min continuously gassed with a mixture of
95 % O2 and 5 % CO2 at 37 °C. After incubation, the
slices were transferred to tissue chambers and perfused
continuously with modified Krebs solution at a rate of
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0.5 ml/min. After a 60-min pre-perfusion, 3-min samples
were collected and assayed for [3H]DA. Oxidative stress
was modelled by addition of H2O2 (250 μM) to the
Krebs solution, starting at the 9th min of collection.
Compounds were added to the perfusion fluid 18 min
prior to H2O2 application. In other experiments, slices
were subjected to electrical field stimulation (EFS1,
EFS2) twice, using a Grass S88 stimulator, with the fol-
lowing parameters: 25 V, 1 msec, 2 Hz, 240 shocks and
SZV558 was administered 18 min before EFS2 and on-
wards. Tritium was measured with a Packard 1900 TR
liquid scintillation counter using an internal standard.
The release of tritium was calculated in Bq/g and
expressed as percentage of the amount of radioactivity
in the tissue at the time of sample collection (fractional
release, FR %). The evoked release of [3H]DA and its
tritiated metabolites in the presence/absence of drugs
was expressed as the net release evoked by H2O2/EFS
and was calculated by the area-under-the-curve (AUC)
method, i.e. subtracting the resting release calculated in
the prestimulation period, from the release measured
during H2O2/EFS.
HPLC analysis
DA and DA metabolites in the tissue extract and super-
fusate were measured using electrochemical and liquid
scintillation detection. Tissue slices were immediately
frozen in liquid nitrogen after termination of the experi-
ment. Weighed frozen tissue was homogenized in an ap-
propriate volume of ice-cold 0.1 M PCA that contained
theophylline (as an internal standard) at 10 nmol/ml
concentration and 0.5 mM sodium metabisulphite (anti-
oxidant for biogenic amines). The suspension was centri-
fuged at 300 g for 10 min at 0–4 °C. The perchloric
anion was precipitated by addition of 10 μl of 1 M KOH
to 190 μl supernatant. Precipitate was then removed by
centrifugation. Supernatant was kept at −20 °C until ana-
lysis. The pellet was saved for protein measurement ac-
cording to [59].
During the collection time the tissue perfusate was
acidified with 10 μl of 1 M perchloric acid. The perfu-
sion fluid was centrifuged at 300 g for 10 min at 0–4 °C;
the supernatant was kept at −20 °C until analysis. The
identification of tritium labeled compounds was based
upon known retention times of unlabeled standards.
For the analysis, 1050-μl sample volumes were diluted
with 50 μl of 10−5mol/l theophylline as an internal
standard and 1000 μl injected. The analytic separations
were performed on a Supelcosil LC-C18DBC18 DB
(150 × 4.6 mm I.D., 3 μm particle size) column from
Sigma-Supelco (Steinheim, Germany) as described pre-
viously [20]. The detector layouts were connected to
Gilson 715 and Agilent data acquisition systems.
Radioactivity of each 1-min effluent samples was deter-
mined by liquid scintillation counting. The [3H]activity
of superfusate samples were quantified using the fol-
lowing formula:
R ¼ 100  sum Aið Þ= Ao−Ainj
 
;
Where the activity of sample is (Ao); the activity of the
injection waste is (Ainj); the activity of 1 min effluent is
(Ai). Content of DA, 3,4-dihydroxyphenylacetaldehyde
(DOPAL), 3,4-dihydroxyphenylethanol (DOPET), 3,4-
dihydroxyphenylacetic acid (DOPAC), homovanilic acid
(HVA), DAQ, tyramine (TYR), 3-methoxityramine (3-
MT) and beta-phenyl-ethylamine (PEA) were expressed
in pmol/mg protein or as percentage of the total tritium
label measured in the sample.
MPTP and MPP+ levels in tissue slices was deter-
mined by HPLC with UV detection, and the UV
detector signal (set at 253 nm) was used for the quanti-
fications. The standards MPTP-HCl and MPP+ iodide
were purchased from Sigma-Aldrich. Data were calcu-
lated by internal standard calibration, and expressed as
pmol/mg protein.
Tyrosine hydroxylase (TH) immunohistochemistry
following in vitro incubation
Male Wistar rats (200–220 g) were used in the experi-
ments. The animals were decapitated under light CO2
anesthesia and brains were quickly removed and incised
in the middle, so the hemispheres could be handled
separately. Blocks containing the substantia nigra were
dissected. There were five treatment groups: control,
incubation with rotenone, rotenone + H2O2, rotenone +
H2O2 + rasagiline (100 nM) and rotenone + H2O2 +
SZV558 (100 nM). Control tissue was incubated in
Krebs solution (60 min, 37 °C), then perfused with the
Krebs solution for 120 min. The rotenone group was
treated with 10 μM rotenone during the incubation
period (60 min, 37 °C), then the same protocol was
continued as for the control group. The rotenone +
H2O2 treated group was identical to the rotenone
protocol, except that perfusion with Krebs solution
(70 min) was followed by perfusion with Krebs solution
containing 250 μM H2O2 (50 min). In cases of rotenone +
H2O2 + rasagiline and rotenone +H2O2 + SZV558 groups,
after incubation with rotenone, the tissues were perfused
with Krebs solution (50 min), then were subjected to 100
nM rasagiline/SZV558 perfusion (20 min), and then to
250 μM H2O2 and 100 nM rasagiline/SZV558 perfusion
(50 min). Each incubated block was immersion fixed with
4 % paraformaldehyde (PFA) overnight, then washed with
0.1 M phosphate buffer (PB). The whole substantia nigra
was sectioned with a vibratome at 40 μm thickness be-
tween and all coronal midbrain sections were collected in
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a systematic random fashion. Ten consecutive sections
were used for immunostaining. All sections were proc-
essed together and the same batch of reagents was used.
Non-specific endogen peroxidase activity was blocked by
0.3 % H2O2 in methanol for 20 min. To reduce non-
specific binding Vector blocking solution (2.5 % normal
horse serum) was applied for 2 h at room temperature.
The primary antibody, anti-tyrosine hydroxylase (rabbit
polyclonal IgG, Merck Millipore) was used in a 1:1000
dilution in 0.1 M PB overnight at 4 °C. After carefully
washing three times with 0.1 M PB, the ready-to-use
secondary antibody (The ImmPRESS Universal Anti-
body Kit, anti-mouse/rabbit) and ImmPACT DAB as
chromogen (both purchased from Vector Laboratories,
Burlingame, CA) was applied according to the manu-
facturer’s instructions. The sections were dried on glass
slides, cleared with xylene and coverslipped with Depex
(Sigma, Aldrich Co, St. Louis, MO, USA).
Digitalization was performed by means of a Pannoramic
P250 scanner (3DHISTECH, Budapest, Hungary) using 9
optical layer with a resolution of 0.11 μm/pixel. The same
areas and number of sections were investigated. Pictures
were taken at 40x magnifications. The contours of
substantia nigra pars compacta were traced in every
other serial section (n = 5, spaced at 80 μm from
each other) according to the online-available Paxinos
Rat Brain Atlas/https://gaidi.ca/rat-brain-atlas/?ml=2&ap=
−5.4&dv=8.7/. The stained cells were counted manually
by two independent investigators, marked with a marker
counter function of the Pannoramic Viewer 1.15.4 digital
slide viewer software application provided by 3DHIS-
TECH, Budapest, Hungary.
In vivo acute 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
(MPTP) model
In this set of experiments, a widely used acute MPTP
protocol was applied, established by numerous previous
studies [32]. Adult (2–3 month old, 30 g) male C57/Bl6
mice (Charles-River, Hungary) were used and randomly
assigned to pre-defined experimental groups. Briefly,
MPTP (Sigma) was injected (4x20 mg/kg i.p) 2 h apart,
and 72 h after the last MPTP treatment animals were
euthanized under light CO2 anesthesia and biogenic
amine content of the striatum analyzed by HPLC-EC
analysis. Control animals received saline injections in an
identical way. The motor function was evaluated 2 h and
1 day after the last MPTP treatment by the open field
and rotarod tests, respectively. Test compounds were
applied in a single, 0.1-20 mg/kg dose i.p. 18 h prior to
the MPTP treatment, or per os (20 mg/kg) using a gav-
age. In other experiments test compounds were applied
in a single dose (10 mg/kg i.p.) 2 h, or 42 h before the
first dose of MPTP. In all experiments animals were
daily monitored for general health and overt side effects.
Behavioral analyses
Open field test
The open field test is the most commonly used method
to measure alterations of behavioral activity after MPTP
treatment [60]. Animals were transferred to the experi-
mental room at least 3 days prior to testing. C57/Bl6
mice were treated with MPTP as described above and
placed 2 h after the final MPTP injection for 30 min into
the open field arena, following a protocol used to test
putative antiparkinsonian drugs on locomotion [61, 62].
Experiments were performed in the light phase under
dimmed lights (~3 lux). Each animal was placed in the
center of a nontransparent plexiglas arena (dimensions:
40x40x40 cm) for a habituation period of 30 min, and
the locomotor activity of animals recorded for 30 min
using a video camera positioned above the arena. The
total distance in meters was provided for the 30 min of
the experiment.
Rotarod test
Motor coordination was tested on the IITC (Woodland
Hills, CA, USA) Rotarod Apparatus, which enables the
simultaneous examination of five mice or rats. Because
mice with striatal dopamine depletion show only mild or
no deficit on the typical accelerating rotarod test, the
modified protocol of Shiotsuki [63] was followed. In this
version mice are tested on a larger drum with fixed
speed to obtain a steep learning curve and therefore this
test is more selective for motor skill learning rather than
maximal gait performance. The apparatus consists of
five separated compartments, with an 8 cm diameter ro-
tating rod 25 cm above the base of the apparatus. Motor
coordination of animals was tested for 180 s with a fix
speed of 10 rpm. Mice were acclimatized to the rotarod
in two trials (180 s) per days for 2 consecutive days before
the start of the experiment. On the test day, 1 h before
drug administration, baseline latencies to fall were deter-
mined. The animals were then treated with sterile saline
or test compounds, followed by MPTP as described above.
6 and 24 h after the final MPTP treatment, the falling la-
tency was measured again in the 180 sec test period. The
latency time to fall was expressed in seconds.
In vivo subchronic MPTP model
Two to three month old, male C57/Bl6 mice
(Charles-River, Hungary) were treated daily with sa-
line or MPTP (30 mg/kg i.p) for 5 consecutive days
before the test compounds were delivered for 21 days
[33, 34]. The MPTP group received vehicle treatment
for the same period after the MPTP treatment. In
contrast to the acute MPTP model, using this proto-
col, dopaminergic neurons degenerate in a delayed,
apoptotic manner [34]. After the experiments,
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endogenous dopamine content in the striatum was
determined using the HPLC method described above.
Chronic protocol of MPTP plus probenecid (MPTPp)
Experiments were performed on 3-month-old male
C57Bl/6 J mice (Charles River, Italy) treated with vehicle
plus probenecid, or MPTP (25 mg/kg i.p.) plus probenecid
(100 mg/kg i.p.), administered 30 min before each MPTP
administration (MPTPp), twice a week for 5 weeks, alone,
or in the presence of the SZV558 (1 mg/kg i.p.) or rasagi-
line (1 mg/kg i.p.) administered 18 h before each MPTPp
administration. At the end of treatment, mice were tested
behaviorally (motility test, beam-walking test, inverted
grid test and olfactory test) to evaluate the motor and ol-
factory performance impairments. Animals were sacrificed
3 days after the last administration of MPTPp. Dopamin-
ergic neurodegeneration was studied in the striatum and
SNc by immunohistochemical evaluation of TH-positive
neurons and Nissl staining.
Spontaneous motor activity: motility test
Spontaneous motility was assessed 2 days before the
MPTPp treatment and 1 day after the last MPTPp admin-
istration, in a quiet isolated room. Mice were placed indi-
vidually in plexiglass cages (length 47 cm, height 19 cm,
width 27 cm), with a metal grid over the floor, and
equipped with infrared photocell emitters-detectors situ-
ated along the long axis of each cage (Opto-Varimex Mini;
Columbus Instruments). The interruption of a photocell
beam was detected by a counter that recorded the total
number of photocell beam interruptions. The counter re-
corded two different types of motor activity: locomotor ac-
tivity due to the locomotion of the mouse along the axes
of the cage and total motor activity due to locomotion
plus non-finalized movements (stereotyped behaviors,
such as grooming, rearing, and sniffing). The counter rec-
ognized the stereotyped movements because of the con-
tinuous interruption of the same photocell beam, whereas
locomotion along the cage produced interruptions of dif-
ferent photocell beams. Motility was detected as soon as
the mouse entered into the cage and was evaluated for
60 min [64].
Beam-walking test
The motor performance and coordination of mice were
evaluated with the beam-walking test [65]. In this test,
mice were trained to traverse the length of a plexiglass
beam that was divided into four sections of 25 cm each
(1 m total length). Each section of the beam had a differ-
ent width: 4, 3, 2, and 1 cm; the beam was placed on a
table and ended in the animal’s home cage. Mice re-
ceived 2 days of training before testing. On the first day,
mice received two assisted trials, involving the
placement of the mouse on one extremity of the beam
with the home cage in close proximity to the animal.
This encourages forward movement along the beam.
After two assisted trials, mice were able to traverse the
entire length of the beam unassisted. Days 1 and 2 of
training ended when all animals had completed five un-
assisted runs across the entire length of the beam. To in-
crease the difficulty further, on the day of the test, a
mesh grid (1 cm squares) of corresponding width was
placed over the beam surface. The test was performed
2 days after the last MPTPp administration and mice
were videotaped for a total of five trials. An error was
counted when, during a forward movement, a limb
slipped through the grid. By scoring each limb slip indi-
vidually, the severity of the error could be measured.
The number of steps and the number of errors were cal-
culated across all five trials and averaged for each group
[65].
Inverted grid test to evaluate grasp strength
The inverted grid test was used to assess skilled forepaw
use, especially related to the distal musculature and digit
manipulations. Mice were placed in the center of a hori-
zontal square grid (15 cm2) consisting of a wire mesh
(mesh 0.5 cm2) surrounded by wooden walls. The grid
was placed 20 cm above a tabletop and was rotated up-
side down allowing mice to move freely. The time the
mice took before falling down was recorded. If a mouse
fell from the mesh grid within 10 s, additional trials
were allowed (maximum: three trials) within an interval
of 5 min; in this case, latencies before falling were mea-
sured. The mean ± SEM of three trials was calculated.
Moreover, for each trial, the number of steps and fore-
limb fault per step was rated and compared with con-
trols. No training was performed, but a pre-test was
carried out [66]. The time the mice took before falling
down was measured 2 days after the last MPTPp
administration.
Olfactory test
Mice were food-deprived for 20 h before the olfactory test.
The test was conducted in a clean plastic cage (length
42 cm, height 15 cm, width 24 cm). A smelling pellet was
buried under the bedding (1 cm) in a cage corner. The
mouse was positioned in the center of the cage and the
time to retrieve the pellet and bite it was measured [29].
The retrieval time of the buried pellet was measured 3 days
after the last MPTPp administration.
Immunohistochemistry and cresyl violet for Nissl staining
Three days after the last administration of MPTPp,
the mice were anesthetized with chloral hydrate
(400 mg/kg i.p.), transcardially perfused with 4 % PFA
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in PB (0.1 M, pH 7.4), and their brains removed and used
for immunohistochemistry. Coronal sections (40 μm
thick) were cut on a vibratome. Free-floating sections
were incubated overnight with TH antibody (poly-
clonal rabbit anti-TH, 1:1000, Millipore, USA).
The primary antibody was prepared in PBS plus
Triton solution containing normal goat serum. After
careful washing, the sections were incubated in
proper biotinylated secondary antibody (Vector, UK).
For visualization, avidin-peroxidase protocol (ABC,
Vector, UK) was applied, using 3,3′-diaminobenzidine
(Sigma, Italy) as chromogen. After washing, the
sections were mounted on gelatin-coated slides, air-
dried, dehydrated in ascending concentrations of
ethanol, and cleared with xylene [67].
Adjacent SNc sections were stained with cresyl violet
for the Nissl staining to evaluate cell death in this area.
For TH and cresyl-violet-stained cells immunohisto-
chemistry in the SNc, three sections were sampled (an-
terior–posterior: −2.92 to −3.28 mm from bregma)
according to the atlas of Paxinos and Franklin 2001. For
each mouse, three sections from the striatum (anterior-
posterior: 1.10 mm to 0.62 mm from bregma) were ana-
lyzed for TH.
Analysis of TH-positive fibers in the striatum
Images were digitized in gray scale with a video camera
(Pixelink PL-A686) and TH immunoreactivity analysis
was performed using the Scion Image analysis program
(Scion Corp., USA). The average gray values from white
matter were subtracted from each section to correct for
background immunoreactivity. For each level of stri-
atum, the obtained value was first normalized with
respect to vehicle, and values from different levels
were averaged thereafter.
Analysis of TH-positive cells and Nissl staining in the SNc
Three sections of SNc were captured at 10× magnification;
in each section, the whole left and right SNc area were ana-
lyzed. Images were digitized (PL-A686 video camera, Pixe-
link, Canada) under constant-light conditions. The stained
cells were counted manually by a blind experimenter. The
number of TH-positive cells and Nissl stained neurons was
obtained separately for each SNc level. Thereafter, in order
to obtain an average value from all levels analyzed, the
number of cells/level from each mouse was normalized
with respect to the vehicle. Values from the three levels
were then averaged to generate a mean.
Statistical analysis
Data are expressed as mean ± SEM with n = number of
identical experiments. Statistical analyses were per-
formed using Prism-3 software (version 3.00, Graph Pad,
San Diego, CA). Student’s t test (pairwise comparisons)
and one-way analysis of variance (ANOVA, multiple
comparisons) were used as a statistical analysis, as ap-
propriate. Behavioral results were statistically compared
with a one-way analysis of variance (ANOVA), followed
by Newman-Keuls post hoc test, for comparison be-
tween experimental groups. For neurochemical analyses
and immunohistochemistry experiments, results were
statistically analyzed by one-way ANOVA followed by
Dunnett/Tukey’s post hoc test (for unequal N). Results
were considered significant at P < 0.05.
Materials
The following drugs were used:
Test compounds, i.e. SZV2220, SZV558, SZV2358,
SZV2419, SZV2435 and SZV2533, (for structural formu-
lae, see Table 1) and rasagiline were synthesized accord-
ing to that described earlier [24]. Rotenone, MPTP and
MPP+ were obtained from Sigma-Aldrich (St. Louis,
MO, USA). Probenecid was obtained from Sigma and
dissolved in 5 % NaHCO3. H2O2 and salts used in the
Krebs solution were obtained from Reanal ZRT.,
Budapest, Hungary. The composition of the modified
Krebs solution was as follows: NaCl 113, KCl 4.7, CaCl2
2.5, KH2PO4 1.2, MgSO4 1.2, NaHCO3 25, Na2EDTA
0.03, ascorbic acid 0.3, and glucose 11.5 mM. All solu-
tions were freshly prepared on the day of use.
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Additional file 1: Table S1. The duration of action of SZV558 (10 mg/kg)
i.p. and the effect of its metabolites on endogenous dopamine content in
the striatum and on the survival of animals after in vivo MPTP treatment
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